Ipsen and Inspiration Biopharmaceuticals have restructured their 2010 strategic partnership for the development and commercialization of Inspiration’s recombinant product portfolio: OBI-1, a recombinant porcine factor VIII (rpFVIII) for the treatment of acquired hemophilia A and congenital hemophilia A, and IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with hemophilia B.
 
Under the new agreement, Ipsen gains commercial rights in key territories and Inspiration remains responsible for the worldwide development of OBI-1 and IB1001. Ipsen paid Inspiration $30 million upfront and will pay Inspiration as much as $200 million for regulatory and commercial milestones.
 
Additionally, Ipsen has agreed to invest as much as $20 million in Inspiration and is entitled to appoint two additional members to Inspiration’s board of directors.